Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart bypass upgrade: which Artery-Harvesting technique works best?

NCT ID NCT07720661

Disease control Sponsor: Hamilton Health Sciences Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This trial tests two methods of harvesting the left internal mammary artery for heart bypass surgery. One method strips the artery clean of surrounding tissue; the other leaves the tissue intact. Researchers want to know which approach keeps the graft open longer and reduces the risk of infection and chronic chest pain. About 1,100 adults undergoing planned bypass surgery will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
skeletonized or non-skeletonized harvesting of the left internal mammary artery during coronary artery bypass surgery
What this could lead to
If one technique proves superior, it could reduce graft failure, infections, and chronic chest pain after bypass surgery.
What could go wrong
This is a surgical technique comparison, not a new drug or device, so improvements may be modest. Results depend on surgeon skill and patient factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older 2. Undergoing isolated CABG surgery with median sternotomy and a planned LIMA-LAD graft 3. Provision of written informed consent Exclusion Criteria: 1. Non-sternotomy surgical approach (e.g., minimally invasive, thoracotomy) 2. Emergency surgery (defined as surgery required within 24 hours of presentation) 3. History of prior sternotomy 4. Currently receiving systemic antibiotics or with an active bacterial infection at the time of surgery 5. History of chronic sternal pain prior to the index surgery 6. Known left subclavian artery stenosis (\>50%) 7. Previous radiation therapy to the chest 8. Known allergy or contraindication to iodinated contrast media that cannot be managed with premedication 9. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m² at baseline (relative contraindication to CTA contrast) as determined based on each centre's laboratory standard. 10. Known pregnancy or plans for pregnancy during the study period 11. Life expectancy less than 1.5 years due to non-cardiac conditions 12. Inability or unwillingness to comply with follow-up procedures including CTA at 1.5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery bypass grafting are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Surgical Wound Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery bypass grafting Coronary artery disease Surgical site infection

More trials for these conditions

Other studies related to the condition(s) this trial covers.